Dr. Reddy's Appoints Dr. Sripada Chandrasekhar as President and Global Head of Human Resources

Dr. Reddy's Appoints Dr. Sripada Chandrasekhar as President and Global Head of Human Resources

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's has announced the appointment of Dr. Sripada Chandrasekhar as the President and Global Head of Human Resources; he will also be a member of Dr. Reddy's Management Council. With over 30 years of experience, Dr. Chandrasekhar brings a rare blend of experience across India's leading firms in Public, Private and Multi-National sectors - both in the early economy areas of steel and manufacturing as well as in the more recent domains of Telecom, IT Services and Consulting.

Prior to joining Dr. Reddy's, Dr. Chandrasekhar worked with IBM in India as Vice President and Head of Human Resources for the India/South Asia region. He was a key member of their India Leadership Team and a Director on the Board of IBM India.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to:

www.drreddys.com

Contacts

Dr. Reddy's Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
[email protected]
or
Saunak Savla, +91-40-49002135
[email protected]
or
Milan Kalawadia (USA), +1 908-203-4931
[email protected]
or
Media:
S Rajan, +91-40-49002445
[email protected]

EmailEmail

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.